Sirturo bedaquiline regulatory update

By WIR Staff | Dec 3, 2012 | 8:00 AM GMT

FDA's Anti-Infective Drugs Advisory Committee voted 18-0 that efficacy data for Sirturo bedaquiline from Johnson & Johnson supported accelerated approval to treat multi-drug-resistant tuberculosis. The panel voted 11-7 that J&J provided substantial safety data.

Panel members were

Read the full 370 word article

How to gain access

Continue reading with a
two-week free trial.